Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC9204-1177 Pharmacokinetics and CYP450 Interaction Study
NCT04059367Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2019
- Primary completion
- Jan 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NN1177 in obesity and Overweight, sponsored by Novo Nordisk. Primary endpoints: Area under the plasma concentration-time curve extrapolated to infinity of caffeine at Day 78, Area under the plasma concentration-time curve extrapolated to infinity of omeprazole at Day 78 and 3 more. Started Aug 2019; status: completed.
02
Drugs
NN1177
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04059367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04059367.